France – Motor vehicles – Système d'acquisition dynamique pour l'achat de véhicules neufs ou d'occasion pour le parc automobile de la communauté de communes Auray Quiberon terre Atlantique.
Research Opportunities in Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)
grants.gov
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages grant applications to support research in cancer epi...
GrantCash GrantUnited StatesOpen
AmountNot provided on the source page. Please check the official source.
DeadlineJul 5, 2029
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages grant applications to support research in cancer epidemiology cohort studies that address specific knowledge gaps in cancer etiology and survivorship. Applications should include hypothesis-based research, support for cohort infrastructure and/or maintenance, continued follow-up, and sharing of data and biospecimen resources as appropriate.
GRA
Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)
grants.gov
This Notice of Funding Opportunity (NOFO) encourages collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengin...
GrantCash GrantUnited StatesOpen
AmountAward ceiling: $500,000
DeadlineJul 5, 2029
This Notice of Funding Opportunity (NOFO) encourages collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods, and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical, or translational science. This NOFO will support clinical trials that test functionality or validate performance in the chosen setting. This NOFO is not intended to support conventional clinical trials that lack translation as the primary motivation. Applications that propose phase III clinical trials in any...
GRA
Causal Hypotheses on the Oral-Systemic Health Impacts of Human Behaviors among People with Chronic Conditions (U01 Clinical Trial Not Allowed)
grants.gov
This Notice of Funding Opportunity (NOFO) invites applications for innovative research on the factors that cause human behaviors and the oral-systemic...
GrantMixedUnited StatesOpen
AmountAward ceiling: $500,000
DeadlineJul 5, 2029
This Notice of Funding Opportunity (NOFO) invites applications for innovative research on the factors that cause human behaviors and the oral-systemic health impacts of those behaviors to enhance health, lengthen life, and reduce illness and disability among people with chronic conditions. Causal hypotheses may include biological, biopsychosocial, congenital, environmental, interpersonal, neurological, psychological, and comorbidity factors that individually, sequentially, or in combination trigger human behaviors and oral-systemic health outcomes, with impacts that may be direct or traceably distal. Applications that propose projects to develop or refine causal hypotheses also are encouraged.
This notice of funding opportunity (NOFO) encourages applications for implementation of investigator-initiated, milestone driven clinical trials that...
GrantMixedUnited StatesOpen
AmountNot provided on the source page. Please check the official source.
DeadlineJul 5, 2029
This notice of funding opportunity (NOFO) encourages applications for implementation of investigator-initiated, milestone driven clinical trials that need enhanced oversight, and as applicable, include mechanistic studies. Mechanistic work in clinical trials may be of great value because it promotes the understanding of human diseases and the development of future therapeutic modalities. Support is available for clinical trials up to 5 years, as well as for extended clinical trials of 6- or 7-years.Investigators are encouraged to visit this NIH website for additional information about the overall mission and research areas of NIAID.Only one clinical trial may be proposed in each NIAID Clinical Trial Implementation Cooperative Agreement (U01) application. In accordance with NIH standard peer-review processes, the applications will be peer-reviewed, and only meritorious applications will be considered.
GRA
NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
grants.gov
This Notice of Funding Opportunity (NOFO) will support, through the cooperative agreement mechanism, investigator-initiated observational studies or b...
GrantMixedUnited StatesOpen
AmountAward ceiling: $500,000
DeadlineJul 5, 2029
This Notice of Funding Opportunity (NOFO) will support, through the cooperative agreement mechanism, investigator-initiated observational studies or biomarker validation studies that require prospective collection of data/biospecimens or continued analysis of data/biospecimens.
TEN
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Perampanel, ATC N03AX22 für die Zeit 01.09.2026 - 31.08.2028 (zzgl. Verlängerungsoption 1x12 Monate)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Brivaracetam, ATC N03AX23 für die Zeit 01.09.2026 - 31.08.2028 (zzgl. Verlängerungsoption 1x12 Monate)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Betamethason + Clotrimazol, ATC D01AC20 für die Zeit 01.09.2026 - 31.08.2028 (zzgl. V.-Option 1x12 Monate)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Capsaicin, ATC N01BX04 für die Zeit 01.09.2026 - 31.08.2028 (zzgl. Verlängerungsoption 1x12 Monate)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Hydrocortison (ausschl. Dafo. TVW), ATC H02AB09 für die Zeit 01.09.26 - 31.08.28 (zzgl. V.-Option 1x12 Mon)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Clotrimazol + Hydrocortison, ATC D01AC20 für die Zeit 01.09.2026 - 31.08.2028 (zzgl. V.-Option 1x12 Monate)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Cefadroxil (ausschl. Dafo. TAB), ATC J01DB05 für die Zeit 01.09.2026 - 31.08.2028 (zzgl. V.-Option 1x12 Mon)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Perindopril arginin + Amlodipin + Indapamid, ATC C09BX01 f. d. Z. 01.9.26-31.8.28 (zzgl. V.-Option 1x12 Mon)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Brinzolamid + Brimonidin, ATC S01EC24 für die Zeit 01.09.2026 - 31.08.2028 (zzgl. V.-Option 1x12 Monate)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Miconazol + Flupredniden, ATC D01AC20 für die Zeit 01.09.2026 - 31.08.2028 (zzgl. V.-Option 1x12 Monate)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Cefixim (ausschl. Dafo. FTA), ATC J01DD08 für die Zeit 01.09.2026 - 31.08.2028 (zzgl. V.-Option 1x12 Mon)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Lidocain, ATC N01BB02 für die Zeit 01.09.2026 - 31.08.2028 (zzgl. Verlängerungsoption 1x12 Monate)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Biperiden (ausschl. Wirkstärke 4mg), ATC N04AA02 für die Zeit 01.09.26 - 31.08.28 (zzgl. V.-Option 1x12 Mon)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Oxybutynin (ausschl. Dafo. PFT), ATC G04BD04 für die Zeit 01.09.26 - 31.08.28 (zzgl. V.-Option 1x12 Monate)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Olanzapin (ausschl. Dafo. TRS), ATC N05AH03 für die Zeit 01.09.2026 - 31.08.2028 (zzgl. V.-Option 1x12 Mon)
Spain – Translation services – SISTEMA DINÁMICO DE COMPRA PARA LA CONTRATACIÓN DEL SERVICIO DE TRADUCCIÓN E INTERPRETACIÓN A DISTINTOS IDIOMASBuyer: Navarra Impulsa Cultura, Deporte y Ocio, S.L. | Notice type: cn-standard | Procedure: restricted | Contract: services | Dea...
Tender
Procurement Contract
Spain
Not provided on the source page. Please check the official source.
France – Motor vehicles – Système d'acquisition dynamique pour l'achat de véhicules neufs ou d'occasion pour le parc automobile de la communauté de communes Auray Quiberon terre Atlantique.Buyer: AURAY QUIBERON TERRE ATLANTIQUE | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2029-07...
Tender
Procurement Contract
France
Not provided on the source page. Please check the official source.
Research Opportunities in Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages grant applications to support re...
Grant
Cash Grant
United States
Not provided on the source page. Please check the official source.
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages grant applications to support research in cancer epidemiology cohort studies that address specific knowledge gaps in cancer etiology and survivorship. Applications should include hypothesis-based research, support for cohort infrastructure and/or maintenance, continued follow-up, and sharing of data and biospecimen resources as appropriate.
44131
Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)This Notice of Funding Opportunity (NOFO) encourages collaborations between the life and physical sciences that: 1) apply a multid...
This Notice of Funding Opportunity (NOFO) encourages collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods, and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical, or translational science. This NOFO will support clinical trials that test functionality or validate performance in the chosen setting. This NOFO is not intended to support conventional clinical trials that lack translation as the primary motivation. Applications that propose phase III clinical trials in any area of research are not sought by and will not be supported through this NOFO. This NOFO does not support commercial production.
44132
Causal Hypotheses on the Oral-Systemic Health Impacts of Human Behaviors among People with Chronic Conditions (U01 Clinical Trial Not Allowed)This Notice of Funding Opportunity (NOFO) invites applications for innovative research on the factors that cause human behaviors a...
This Notice of Funding Opportunity (NOFO) invites applications for innovative research on the factors that cause human behaviors and the oral-systemic health impacts of those behaviors to enhance health, lengthen life, and reduce illness and disability among people with chronic conditions. Causal hypotheses may include biological, biopsychosocial, congenital, environmental, interpersonal, neurological, psychological, and comorbidity factors that individually, sequentially, or in combination trigger human behaviors and oral-systemic health outcomes, with impacts that may be direct or traceably distal. Applications that propose projects to develop or refine causal hypotheses also are encouraged.
44133
NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)This notice of funding opportunity (NOFO) encourages applications for implementation of investigator-initiated, milestone driven c...
Grant
Mixed
United States
Not provided on the source page. Please check the official source.
This notice of funding opportunity (NOFO) encourages applications for implementation of investigator-initiated, milestone driven clinical trials that need enhanced oversight, and as applicable, include mechanistic studies. Mechanistic work in clinical trials may be of great value because it promotes the understanding of human diseases and the development of future therapeutic modalities. Support is available for clinical trials up to 5 years, as well as for extended clinical trials of 6- or 7-years.Investigators are encouraged to visit this NIH website for additional information about the overall mission and research areas of NIAID.Only one clinical trial may be proposed in each NIAID Clinical Trial Implementation Cooperative Agreement (U01) application. In accordance with NIH standard peer-review processes, the applications will be peer-reviewed, and only meritorious applications will be considered.
44134
NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed)This Notice of Funding Opportunity (NOFO) will support, through the cooperative agreement mechanism, investigator-initiated observ...
This Notice of Funding Opportunity (NOFO) will support, through the cooperative agreement mechanism, investigator-initiated observational studies or biomarker validation studies that require prospective collection of data/biospecimens or continued analysis of data/biospecimens.
44135
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Perampanel, ATC N03AX22 für die Zeit 01.09.2026 - 31.08.2028 (zzgl. Verlängerungsoption 1x12 Monate)Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2029-07-05
Tender
Procurement Contract
Germany
Not provided on the source page. Please check the official source.
France – Vehicle-fleet management services – Système d'acquisition dynamique pour l'acquisition et location de véhicules - 2026 à 2030Buyer: Le Mans Métropole Habitat | Notice type: cn-standard | Procedure: restricted | Contract: services | Deadline: 2029-07-05
Tender
Procurement Contract
France
Not provided on the source page. Please check the official source.
